Company profile: OrthoSera
1.1 - Company Overview
Company description
- Provider of serum-based orthobiologics and regenerative medicine products leveraging blood serum and plasma. Markets coating technology for human dental bone grafts. Offerings include BoneAlbumin, a serum albumin-coated bone allograft for bone regeneration, Vérplazma derived from blood plasma, and Hiperakut szérum, a hyperacute serum for regenerative applications.
Products and services
- BoneAlbumin: An orthobiologic-grade serum albumin–coated bone allograft engineered for bone regeneration, marketed for human dental bone graft applications using albumin coating on processed allogeneic bone
- Hiperakut szérum (Hyperacute Serum): A serum-based product used in regenerative medicine, potentially reducing inflammation or promoting healing, aligned with OrthoSera’s approach of harnessing blood serum for human diseases
- Vérplazma (Blood Plasma): A plasma-derived product used in regenerative medicine applications, integrating blood plasma into OrthoSera’s serum-based orthobiologics for applications addressing human diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OrthoSera
Immatics
HQ: Germany
Website
- Description: Provider of TCR-based cancer immunotherapies and discovery platforms, including ACTengine personalized TCR cell therapy, ACTallo off-the-shelf gamma delta T-cell therapies with TCRs or CARs, TCER bispecific T-cell engaging receptors, and the XPRESIDENT, XCEPTOR, and XCUBE platforms for target identification, TCR discovery/engineering, and AI-powered immunoinformatics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immatics company profile →
BlueRock Therapeutics
HQ: Canada
Website
- Description: Provider of induced pluripotent stem cell (iPSC) therapies using an industry-leading platform, with programs including bemdaneprocel for Parkinson’s disease, OpCT-001 for primary photoreceptor diseases to restore vision, BR-CM01 to replace damaged heart cells after myocardial infarction or heart failure, and pre-clinical Treg-based therapies for autoimmune disorders; conducts clinical trials to assess safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueRock Therapeutics company profile →
Marker Therapeutics
HQ: United States
Website
- Description: Provider of a clinical-stage, non-genetically engineered multi-antigen T cell therapy platform. Offers MT-401 for post-transplant AML, MultiTAA technology, and conducts ARTEMIS and APOLLO trials for blood and solid tumors. Utilizes a manufacturing process expanding natural T cells to target up to five tumor-associated antigens, with therapies designed for quick outpatient administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marker Therapeutics company profile →
Myst Therapeutics
HQ: United States
Website
- Description: Provider of novel broad-spectrum cancer immunotherapy products and adoptive cell therapies for solid tumors, harnessing a patient's own immune system via enriched tumor-derived T cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myst Therapeutics company profile →
OvaScience
HQ: United States
Website
- Description: Provider of life sciences solutions focused on the discovery, development and commercialization of treatments for infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OvaScience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OrthoSera
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OrthoSera
2.2 - Growth funds investing in similar companies to OrthoSera
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OrthoSera
4.2 - Public trading comparable groups for OrthoSera
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →